Supernus Pharmaceuticals, Inc. (SUPN) 10-Year Financial Performance & Capital Metrics

SUPN • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsCNS & Pain Management

AboutSupernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.Show more

Revenue $662M +8.9%
EBITDA $162M +103.6%
Net Income $74M +5512.8%
EPS (Diluted) 1.32 +5469.6%
Gross Margin 88.23% +2.3%
EBITDA Margin 24.49% +86.9%
Operating Margin 12.34% +1522.8%
Net Margin 11.16% +5052.8%
ROE 7.55% +5083.9%
ROIC 6.49% +1844.5%
Debt/Equity 0.03 -26.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong Piotroski F-Score: 8/9
✓FCF machine: 25.9% free cash flow margin
✓Momentum leader: RS Rating 81 (top 19%)
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 11.0%

✗Weaknesses

✗Weak 3Y average ROE of 4.9%

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y18.42%

5Y11%

3Y4.51%

TTM4.54%

Profit (Net Income) CAGR

10Y14.03%

5Y-8.16%

3Y11.4%

TTM-132.02%

EPS CAGR

10Y15.22%

5Y-8.87%

3Y10.44%

TTM-131.74%

ROCE

10Y Avg15.75%

5Y Avg6.63%

3Y Avg3.75%

Latest7.92%

Peer Comparison

CNS & Pain Management

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NBIXNeurocrine Biosciences, Inc.	13.49B	135.33	41.13	24.81%	15.95%	14.25%	4.13%	0.18
SUPNSupernus Pharmaceuticals, Inc.	2.97B	51.80	39.24	8.94%	-2.8%	-1.82%	5.76%	0.03
PTPIPetros Pharmaceuticals, Inc.	338.98K	0.01	-0.00	-12.2%	-9.68%	-208.53%
QNTMQuantum BioPharma Ltd.	26.94M	7.01	-0.56			-379.78%		0.08
AYTUAytu BioPharma, Inc.	28.02M	2.75	-1.27	1.84%	-20.52%	-56.41%		1.21
AQSTAquestive Therapeutics, Inc.	429.45M	3.52	-6.90	13.8%	-158.95%
AVDLAvadel Pharmaceuticals plc	2.11B	21.50	-42.16	5.05%	-0.11%	-0.28%		0.02
RGCRegencell Bioscience Holdings Limited	17.39B	35.17	-4042.53			-67.02%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	144.43M	215M	302.24M	408.9M	392.75M	520.4M	579.77M	667.24M	607.52M	661.82M
Revenue Growth %	0.18%	0.49%	0.41%	0.35%	-0.04%	0.32%	0.11%	0.15%	-0.09%	0.09%
Cost of Goods Sold+	8.42M	11.99M	15.21M	15.36M	16.66M	52.46M	75.06M	87.22M	83.78M	77.91M
COGS % of Revenue	0.06%	0.06%	0.05%	0.04%	0.04%	0.1%	0.13%	0.13%	0.14%	0.12%
Gross Profit+	136M	203.02M	287.02M	393.54M	376.1M	467.94M	504.71M	580.02M	523.74M	583.91M
Gross Margin %	0.94%	0.94%	0.95%	0.96%	0.96%	0.9%	0.87%	0.87%	0.86%	0.88%
Gross Profit Growth %	0.17%	0.49%	0.41%	0.37%	-0.04%	0.24%	0.08%	0.15%	-0.1%	0.11%
Operating Expenses+	118.34M	148.8M	187.48M	249.1M	227.52M	294.24M	418.69M	533.89M	529.01M	502.25M
OpEx % of Revenue	0.82%	0.69%	0.62%	0.61%	0.58%	0.57%	0.72%	0.8%	0.87%	0.76%
Selling, General & Admin	89.2M	106.01M	137.91M	159.89M	158.43M	200.68M	304.76M	377.22M	336.36M	335.78M
SG&A % of Revenue	0.62%	0.49%	0.46%	0.39%	0.4%	0.39%	0.53%	0.57%	0.55%	0.51%
Research & Development	29.14M	42.79M	49.58M	89.21M	69.1M	75.96M	90.47M	74.55M	91.59M	108.8M
R&D % of Revenue	0.2%	0.2%	0.16%	0.22%	0.18%	0.15%	0.16%	0.11%	0.15%	0.16%
Other Operating Expenses	38K	-15K	0	0	0	17.6M	23.46M	82.12M	101.06M	57.67M
Operating Income+	17.66M	54.22M	99.54M	144.44M	148.57M	173.7M	86.03M	46.12M	-5.27M	81.67M
Operating Margin %	0.12%	0.25%	0.33%	0.35%	0.38%	0.33%	0.15%	0.07%	-0.01%	0.12%
Operating Income Growth %	-0.27%	2.07%	0.84%	0.45%	0.03%	0.17%	-0.5%	-0.46%	-1.11%	16.5%
EBITDA+	18.59M	56.62M	107.67M	151.51M	158.8M	191.84M	118.62M	131.67M	79.59M	162.08M
EBITDA Margin %	0.13%	0.26%	0.36%	0.37%	0.4%	0.37%	0.2%	0.2%	0.13%	0.24%
EBITDA Growth %	-0.26%	2.05%	0.9%	0.41%	0.05%	0.21%	-0.38%	0.11%	-0.4%	1.04%
D&A (Non-Cash Add-back)	921K	2.4M	8.13M	7.06M	10.22M	18.14M	32.59M	85.54M	84.86M	80.41M
EBIT	20.84M	54.22M	99.54M	144.44M	170.19M	192.4M	96.6M	67.81M	5.18M	97.87M
Net Interest Income+	-4.09M	-3.62M	1.08M	-4.27M	-1.08M	-5.05M	-12.85M	14.62M	8.04M	16.2M
Interest Income	681K	1.48M	2.65M	13.84M	21.62M	18.7M	10.57M	21.69M	10.45M	16.2M
Interest Expense	4.77M	5.09M	1.57M	18.11M	22.71M	23.75M	23.42M	7.07M	2.42M	0
Other Income/Expense	-6.23M	-3.85M	1.08M	-4.27M	-1.08M	-5.05M	-12.85M	14.62M	8.04M	16.2M
Pretax Income+	14.97M	50.37M	100.62M	140.18M	147.49M	168.65M	73.17M	60.74M	2.77M	97.87M
Pretax Margin %	0.1%	0.23%	0.33%	0.34%	0.38%	0.32%	0.13%	0.09%	0%	0.15%
Income Tax+	956K	-40.85M	43.33M	29.18M	34.43M	41.7M	19.75M	32K	1.45M	24M
Effective Tax Rate %	0.94%	1.81%	0.57%	0.79%	0.77%	0.75%	0.73%	1%	0.48%	0.75%
Net Income+	14.02M	91.22M	57.28M	110.99M	113.06M	126.95M	53.42M	60.71M	1.32M	73.86M
Net Margin %	0.1%	0.42%	0.19%	0.27%	0.29%	0.24%	0.09%	0.09%	0%	0.11%
Net Income Growth %	-0.29%	5.51%	-0.37%	0.94%	0.02%	0.12%	-0.58%	0.14%	-0.98%	55.13%
Net Income (Continuing)	13.94M	91.22M	57.28M	110.99M	113.06M	126.95M	53.42M	60.71M	1.32M	73.86M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.28	1.76	1.08	2.05	2.10	2.36	0.98	1.04	0.02	1.32
EPS Growth %	-0.13%	5.29%	-0.39%	0.9%	0.02%	0.12%	-0.58%	0.06%	-0.98%	54.7%
EPS (Basic)	0.29	1.84	1.13	2.13	2.16	2.41	1.01	1.13	0.02	1.34
Diluted Shares Outstanding	51.16M	51.71M	53.3M	54.1M	53.82M	53.69M	54.36M	61.68M	55.51M	55.96M
Basic Shares Outstanding	47.49M	49.47M	50.76M	51.99M	52.41M	52.62M	53.1M	53.67M	54.54M	55.1M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	105.98M	151.4M	228.45M	493.49M	472.64M	630.42M	601.59M	734.15M	493.11M	686.07M
Cash & Short-Term Investments	62.19M	90.12M	140.04M	356.02M	347.07M	422.53M	339.68M	461.33M	254.87M	453.61M
Cash Only	62.19M	90.12M	100.3M	192.25M	181.38M	288.64M	203.43M	93.12M	75.05M	69.33M
Short-Term Investments	0	0	39.74M	163.77M	165.69M	133.89M	136.25M	368.21M	179.82M	384.28M
Accounts Receivable	25.91M	41.53M	65.59M	102.92M	87.33M	140.88M	148.93M	165.5M	144.16M	142.08M
Days Sales Outstanding	65.48	70.5	79.21	91.87	81.16	98.81	93.76	90.53	86.61	78.36
Inventory	12.59M	16.8M	16.3M	25.66M	26.63M	48.33M	85.96M	91.54M	77.41M	54.29M
Days Inventory Outstanding	545.44	511.63	391.12	609.89	583.39	336.24	417.99	383.08	337.24	254.37
Other Current Assets	0	2.96M	6.52M	8.89M	0	0	0	15.78M	16.68M	36.09M
Total Non-Current Assets+	82.75M	158.16M	196.01M	484.32M	687.64M	873.68M	1.09B	968.36M	784.56M	682M
Property, Plant & Equipment	3.87M	4.34M	5.12M	4.09M	17.07M	37.82M	16.95M	15.17M	13.53M	11.54M
Fixed Asset Turnover	37.28x	49.49x	58.98x	99.85x	23.01x	13.76x	34.19x	43.98x	44.90x	57.32x
Goodwill	0	0	0	0	0	77.91M	117.52M	117.02M	117.02M	117.02M
Intangible Assets	976K	16.49M	36.02M	31.37M	24.84M	364.34M	784.69M	702.46M	599.89M	521.91M
Long-Term Investments	55.01M	75.41M	133.64M	418.8M	591.77M	350.36M	119.17M	93.9M	16.62M	0
Other Non-Current Assets	391K	20.19M	389K	380K	21.89M	43.25M	49.23M	39.81M	37.51M	31.53M
Total Assets+	188.73M	309.57M	424.46M	977.81M	1.16B	1.5B	1.69B	1.7B	1.28B	1.37B
Asset Turnover	0.77x	0.69x	0.71x	0.42x	0.34x	0.35x	0.34x	0.39x	0.48x	0.48x
Asset Growth %	0.37%	0.64%	0.37%	1.3%	0.19%	0.3%	0.12%	0.01%	-0.25%	0.07%
Total Current Liabilities+	56.1M	80.74M	123M	161.35M	160.59M	245.11M	315.38M	687.96M	290.2M	292.4M
Accounts Payable	4.31M	8.05M	6.84M	3.19M	10.14M	6.15M	9.33M	10.54M	1.96M	4.59M
Days Payables Outstanding	186.94	245.29	164.18	75.94	222.18	42.77	45.37	44.12	8.56	21.49
Short-Term Debt	497K	0	4.28M	2.18M	0	0	0	401.97M	0	0
Deferred Revenue (Current)	176K	209K	287K	-1000K	0	0	0	0	0	0
Other Current Liabilities	26.79M	63.33M	17.03M	22.99M	14.47M	55.99M	93.04M	54.95M	77.08M	68.56M
Current Ratio	1.89x	1.88x	1.86x	3.06x	2.94x	2.57x	1.91x	1.07x	1.70x	2.35x
Quick Ratio	1.66x	1.67x	1.72x	2.90x	2.78x	2.37x	1.63x	0.93x	1.43x	2.16x
Cash Conversion Cycle	423.98	336.83	306.15	625.82	442.37	392.28	466.38	429.49	415.3	311.24
Total Non-Current Liabilities+	13.76M	37.07M	33.98M	363.44M	404.27M	514.14M	557.92M	128.35M	65.96M	39.94M
Long-Term Debt	7.08M	4.17M	22.26M	329.46M	345.17M	361.75M	379.25M	0	0	0
Capital Lease Obligations	0	0	0	0	30.44M	48.81M	41.3M	36M	33.2M	27.38M
Deferred Tax Liabilities	854K	114K	14.96M	31.46M	0	35.22M	85.36M	49.81M	24.96M	4.96M
Other Non-Current Liabilities	35.21M	31.41M	10.58M	33.97M	28.66M	68.36M	52.02M	42.54M	7.8M	7.6M
Total Liabilities	69.86M	117.81M	156.98M	524.79M	564.85M	759.24M	873.3M	816.3M	356.16M	332.34M
Total Debt+	7.19M	4.17M	26.54M	329.46M	378.44M	414.32M	427.03M	444.76M	41.53M	34.27M
Net Debt	-55M	-85.96M	-73.76M	137.21M	197.05M	125.69M	223.59M	351.64M	-33.53M	-35.06M
Debt / Equity	0.06x	0.02x	0.10x	0.73x	0.64x	0.56x	0.52x	0.50x	0.05x	0.03x
Debt / EBITDA	0.39x	0.07x	0.25x	2.17x	2.38x	2.16x	3.60x	3.38x	0.52x	0.21x
Net Debt / EBITDA	-2.96x	-1.52x	-0.69x	0.91x	1.24x	0.66x	1.88x	2.67x	-0.42x	-0.22x
Interest Coverage	3.70x	10.65x	63.48x	7.98x	6.54x	7.31x	3.67x	6.52x	-2.18x	-
Total Equity+	118.88M	191.75M	267.48M	453.02M	595.43M	744.86M	815.85M	886.2M	921.52M	1.04B
Equity Growth %	0.67%	0.61%	0.39%	0.69%	0.31%	0.25%	0.1%	0.09%	0.04%	0.12%
Book Value per Share	2.32	3.71	5.02	8.37	11.06	13.87	15.01	14.37	16.60	18.51
Total Shareholders' Equity	118.88M	191.75M	267.48M	453.02M	595.43M	744.86M	815.85M	886.2M	921.52M	1.04B
Common Stock	49K	50K	51K	52K	53K	53K	53K	54K	55K	56K
Retained Earnings	-144.64M	-84.29M	-26.82M	86.49M	199.55M	326.5M	379.92M	481.25M	482.56M	556.43M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-488K	-134K	-747K	-3.16M	7.42M	8.97M	1.54M	-3.21M	-593K	-189K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	32.12M	66.81M	114.64M	128.99M	143.13M	138.4M	127.13M	116.83M	111.08M	171.95M
Operating CF Margin %	0.22%	0.31%	0.38%	0.32%	0.36%	0.27%	0.22%	0.18%	0.18%	0.26%
Operating CF Growth %	3.15%	1.08%	0.72%	0.13%	0.11%	-0.03%	-0.08%	-0.08%	-0.05%	0.55%
Net Income	14.02M	91.22M	57.28M	110.99M	113.06M	126.95M	53.42M	60.71M	1.32M	73.86M
Depreciation & Amortization	921K	2.4M	8.13M	7.06M	6.66M	18.14M	32.59M	85.54M	84.86M	80.41M
Stock-Based Compensation	4.23M	5.93M	8.43M	11.29M	14.85M	16.56M	17.91M	17.57M	26.76M	27.75M
Deferred Taxes	2.15M	-41.79M	21.22M	-4.17M	-5.83M	568K	-4.99M	-26.32M	-25.71M	-20.14M
Other Non-Cash Items	748K	605K	-4.14M	8.54M	13.79M	12.69M	24.62M	3.57M	33M	12.11M
Working Capital Changes	10.06M	8.45M	23.71M	-4.73M	613K	-36.52M	3.57M	-24.24M	-9.14M	-2.05M
Change in Receivables	-8.64M	-15.62M	-24.06M	-35.86M	15.75M	-34.61M	3.87M	-16.37M	18.77M	2.08M
Change in Inventory	854K	-4.21M	497K	-9.36M	-969K	-10.12M	-14.58M	-17.86M	6.11M	15.81M
Change in Payables	2.06M	3.47M	-620K	-3.58M	6.96M	8.27M	18.18M	-19.16M	-36.29M	-15.02M
Cash from Investing+	-36.23M	-35.96M	-86.42M	-413.48M	-157.92M	-34.7M	-81.91M	-216.66M	268.73M	-189.87M
Capital Expenditures	-2.1M	-1.6M	-2.03M	-844K	-2.74M	-3.45M	-2.04M	-412K	-551K	-725K
CapEx % of Revenue	0.01%	0.01%	0.01%	0%	0.01%	0.01%	0%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-8.51M	-18.82M	-11.15M	-809K	1.35M	-241K	12.89M	14K	0	9K
Cash from Financing+	1.87M	2.05M	5.68M	376.44M	3.93M	3.56M	-130.42M	-10.48M	-397.88M	12.19M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	55.25M	0	0	0	-22.9M	-1.99M	-2.71M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	30.02M	65.21M	112.61M	128.14M	140.39M	134.95M	125.08M	116.41M	110.53M	171.23M
FCF Margin %	0.21%	0.3%	0.37%	0.31%	0.36%	0.26%	0.22%	0.17%	0.18%	0.26%
FCF Growth %	3.2%	1.17%	0.73%	0.14%	0.1%	-0.04%	-0.07%	-0.07%	-0.05%	0.55%
FCF per Share	0.59	1.26	2.11	2.37	2.61	2.51	2.30	1.89	1.99	3.06
FCF Conversion (FCF/Net Income)	2.29x	0.73x	2.00x	1.16x	1.27x	1.09x	2.38x	1.92x	84.41x	2.33x
Interest Paid	0	0	134K	1.34M	2.52M	2.52M	2.52M	2.52M	1.95M	0
Taxes Paid	0	0	1.59M	34.77M	51.54M	45.43M	25.19M	16.2M	36.6M	53.25M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	14.74%	58.73%	24.95%	30.81%	21.57%	18.94%	6.85%	7.13%	0.15%	7.55%
Return on Invested Capital (ROIC)	30.17%	47.93%	49.85%	27.64%	16.12%	15.67%	6.76%	3.04%	-0.37%	6.49%
Gross Margin	94.17%	94.43%	94.97%	96.24%	95.76%	89.92%	87.05%	86.93%	86.21%	88.23%
Net Margin	9.7%	42.43%	18.95%	27.14%	28.79%	24.39%	9.21%	9.1%	0.22%	11.16%
Debt / Equity	0.06x	0.02x	0.10x	0.73x	0.64x	0.56x	0.52x	0.50x	0.05x	0.03x
Interest Coverage	3.70x	10.65x	63.48x	7.98x	6.54x	7.31x	3.67x	6.52x	-2.18x	-
FCF Conversion	2.29x	0.73x	2.00x	1.16x	1.27x	1.09x	2.38x	1.92x	84.41x	2.33x
Revenue Growth	18.34%	48.87%	40.57%	35.29%	-3.95%	32.5%	11.41%	15.09%	-8.95%	8.94%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Product	399.87M	383.4M	509.35M	567.5M	649.43M	573.93M	637.7M
Product Growth	-	-4.12%	32.85%	11.42%	14.44%	-11.63%	11.11%
Qelbree	-	-	-	9.88M	61.32M	140.19M	241.27M
Qelbree Growth	-	-	-	-	520.73%	128.62%	72.10%
GOCOVRI	-	-	-	9.78M	104.42M	119.64M	130.82M
GOCOVRI Growth	-	-	-	-	967.92%	14.57%	9.35%
Oxtellar X R	84.58M	88.19M	98.72M	110.71M	115.34M	113.4M	99.46M
Oxtellar X R Growth	-	4.27%	11.95%	12.14%	4.19%	-1.68%	-12.29%
APOKYN	-	-	74.3M	99.23M	75.31M	75.08M	73.93M
APOKYN Growth	-	-	-	33.56%	-24.11%	-0.29%	-1.54%
Trokendi Xr	-	295.21M	319.64M	304.82M	261.22M	94.34M	63.2M
Trokendi Xr Growth	-	-	8.27%	-4.64%	-14.30%	-63.89%	-33.00%
Manufactured Product, Other	-	-	-	-	31.82M	31.28M	29.01M
Manufactured Product, Other Growth	-	-	-	-	-	-1.69%	-7.27%
Royalty, License And Other Revenue	-	-	-	-	-	-	24.12M
Royalty, License And Other Revenue Growth	-	-	-	-	-	-	-
Royalty	8.28M	9.36M	11.05M	12.27M	17.81M	33.59M	-
Royalty Growth	-	13.04%	18.09%	11.08%	45.11%	88.63%	-
MYOBLOC	-	-	9.75M	19.51M	-	-	-
MYOBLOC Growth	-	-	-	100.23%	-	-	-
XADAGO	-	-	6.94M	13.39M	-	-	-
XADAGO Growth	-	-	-	92.81%	-	-	-
Osomolex ER	-	-	-	188K	-	-	-
Osomolex ER Growth	-	-	-	-	-	-	-
License	750K	-	-	-	-	-	-
License Growth	-	-	-	-	-	-	-
Trokendi X R	315.3M	-	-	-	-	-	-
Trokendi X R Growth	-	-	-	-	-	-	-
License Event Based Milestone	750K	-	-	-	-	-	-
License Event Based Milestone Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Supernus Pharmaceuticals, Inc. (SUPN) has a price-to-earnings (P/E) ratio of 39.2x. This suggests investors expect higher future growth.

Growth & Financials

Supernus Pharmaceuticals, Inc. (SUPN) reported $681.5M in revenue for fiscal year 2024. This represents a 84774% increase from $0.8M in 2011.

Supernus Pharmaceuticals, Inc. (SUPN) grew revenue by 8.9% over the past year. This is steady growth.

Supernus Pharmaceuticals, Inc. (SUPN) reported a net loss of $19.1M for fiscal year 2024.

Dividend & Returns

Supernus Pharmaceuticals, Inc. (SUPN) has a return on equity (ROE) of 7.5%. This is below average, suggesting room for improvement.

Supernus Pharmaceuticals, Inc. (SUPN) generated $132.5M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...